Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb/III, Open Label, Single Arm, Multi-centre, Trial to Assess the Immunogenicity and Safety of an Additional Dose Vaccination With a Recombinant Protein RBD Fusion Heterodimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults With Pre-existing Immunosuppressive Conditions Vaccinated Against COVID-19

NCT05303402 is registered in ClinicalTrials.gov with Hipra Scientific, S.L.U as lead sponsor.

NCT NCT05303402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05303402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb/III, Open Label, Single Arm, Multi-centre, Trial to Assess the Immunogenicity and Safety of an Additional Dose Vaccination With a Recombinant Protein RBD Fusion Heterodimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults With Pre-existing Immunosuppressive Conditions Vaccinated Against COVID-19
Lead sponsor
Hipra Scientific, S.L.U
Phase
Phase 2/3
Overall status
Completed
Start date
May 12, 2022
Completion date
December 1, 2023
Enrollment
241 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

sars cov 2 infection